Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)

Summary

To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with symptomatic diabetic peripheral polyneuropathy after 250 ml i.v. infusions once daily for 20 days followed by oral treatment 600 mg × 3 daily for 140 days.

Timeline

Start

2006-12

Primary completion

2008-05

Completion

2008-12

Drugs

Indications